Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms

Authors: Arianna Marinello, MD, Claudia Parisi, MD, Damien Vasseur, PhD, David Combarel, PharmD, Juliette Bihoreau, NP, Pernelle Lavaud, MD, Rémy Ezzedine, MD, Lodovica Zullo, MD, Luc Friboulet, PhD, Gerard Zalcman, MD, PhD, Antoine Italiano, MD, PhD, Benjamin Besse, MD, PhD, Mihaela Aldea, MD, PhD

Source: JTO Clinical and Research Reports, Vol 6, Iss 3, Pp 100773- (2025)

Subject Terms: EGFR-mutated NSCLC, RET fusion, BRAF V600E, Selpercatinib, Trametinib, Case report, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364324001437; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/342ea336baed47408d1a5e3b6965bb2f

Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey

Authors: Marco Tagliamento, MD, Jordi Remon, MD, PhD, Matteo Giaj Levra, MD, Andrea De Maria, MD, Paolo Bironzo, MD, PhD, Benjamin Besse, MD, PhD, Silvia Novello, MD, PhD, Laura Mezquita, MD, PhD

Source: JTO Clinical and Research Reports, Vol 4, Iss 1, Pp 100446- (2023)

Subject Terms: Immune checkpoint inhibitors, Cancer, HBV, HCV, Immunotherapy, Viral hepatitis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364322001709; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/8bb0b046a4dc4b03923440db7ca7bf49

Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial

Authors: Jordi Remon, MD, Benjamin Besse, MD, PhD, Alexandra Leary, MD, PhD, Ivan Bièche, MD, Bastien Job, MD, Ludovic Lacroix, PhD, Aurélie Auguste, PhD, Marjorie Mauduit, PhD, Clarisse Audigier-Valette, MD, Judith Raimbourg, MD, Anne Madroszyk, MD, Stefan Michels, MD, Mohammed Amine Bayar, MD, Marta Jimenez, PhD, Jean-Charles Soria, MD, PhD, Etienne Rouleau, PhD, PharmD, MPH, Fabrice Barlesi, MD, PhD

Source: JTO Clinical and Research Reports, Vol 1, Iss 3, Pp 100068- (2020)

Subject Terms: BRCA mutation, Advanced non–small cell lung cancer, PARP inhibitors, Next-generation sequencing, SAFIR trial, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364320300916; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/cb706811cafb4c91896d59398b20d6b7

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report

Authors: Diego Enrico, MD, Ludovic Lacroix, PharmD, PhD, Jeanne Chen, MD, Etienne Rouleau, PharmD, PhD, Jean-Yves Scoazec, MD, PhD, Yohann Loriot, MD, PhD, Lambros Tselikas, MD, Cécile Jovelet, PharmD, PhD, David Planchard, MD, PhD, Anas Gazzah, MD, Laura Mezquita, MD, PhD, Maud Ngo-Camus, MSc, Stefan Michiels, PhD, Christophe Massard, MD, PhD, Gonzalo Recondo, MD, PhD, Francesco Facchinetti, MD, Jordi Remon, MD, Jean-Charles Soria, MD, PhD, Fabrice André, MD, PhD, Gilles Vassal, MD, PhD, Luc Friboulet, PhD, Benjamin Besse, MD, PhD

Source: JTO Clinical and Research Reports, Vol 1, Iss 2, Pp 100023- (2020)

Subject Terms: EGFR resistance, Oncogene fusions, NSCLC, EGFR tyrosine kinase inhibitors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364320300230; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/1bd1d67570ef49619261081550260f89